Targeting the proteasome in Leishmania donovani: developments from preclinical to Phase I and ii trials. (PubMed, Expert Opin Investig Drugs) - Oct 15, 2026 - "Current treatments, including liposomal amphotericin B, miltefosine, paromomycin, and pentavalent antimonials, are limited by emerging resistance, high cost, cold storage, need for parenteral administration...It covers the preclinical story of GSK3494245 to the story of proteasome inhibitors, especially LXE408, which has progressed from Phase I evaluation to Phase II clinical trials in India and Ethiopia...Proteasome inhibitors provide strong antiparasitic activity, high selectivity and a potential for oral treatment. If the ongoing clinical trials show safety, efficacy and durable cure rates, proteasome-targeting drugs will revolutionize VL therapy and be a model for drug development against other neglected tropical diseases."
Journal • P1 data • Preclinical • Review • Infectious Disease
|
|
Priya Maurya; Rajiv Kumar; Sarita Singh; Shyam Sundar; Vishal Kumar Singh
|